MedTrace Logo

Double-blind Clinical Trials of Probiotic Products in Oral Health.

NCT04289337 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 130

Last updated 2020-02-28

No results posted yet for this study

Summary

In order to evaluate the effects of supplementary probiotics and their metabolites on oral environment and oral microbiota, Taiwan FDA No. 88037803 will be used to evaluate the effects of oral probiotic candidate strains from previous research results and develop oral probiotic products.

Conditions

  • Probiotics
  • Oral Health
  • Probiotic Metabolites

Interventions

DIETARY_SUPPLEMENT

Combined probiotics (1)

Subjects used one oral combined probiotics (1) tablet each morning, noon, and evening for 4 weeks.

DIETARY_SUPPLEMENT

Combined probiotics (2)

Subjects used one oral combined probiotics (2) tablet each morning, noon, and evening for 4 weeks.

DIETARY_SUPPLEMENT

Combined heat-killed probiotics (1)

Subjects used one oral combined heat-killed probiotics (1) tablet each morning, noon, and evening for 4 weeks.

DIETARY_SUPPLEMENT

Combined heat-killed probiotics (2)

Subjects used one oral combined heat-killed probiotics (2) tablet each morning, noon, and evening for 4 weeks.

DIETARY_SUPPLEMENT

Probiotic metabolites

Subjects used one oral probiotic metabolites tablet each morning, noon, and evening for 4 weeks.

DIETARY_SUPPLEMENT

Placebo

Subjects used one oral placebo tablet each morning, noon, and evening for 4 weeks.

Sponsors & Collaborators

  • Glac Biotech Co., Ltd

    lead INDUSTRY

Principal Investigators

  • Hsieh-Hsun Ho, Ph.D. · Glac Biotech Co., Ltd

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-10-21
Primary Completion
2019-12-02
Completion
2019-12-06

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04289337 on ClinicalTrials.gov